Abstract
RNAi is a powerful research tool for specific gene silencing and may also lead to promising novel therapeutic strategies. However, the development of RNAi-based therapies has been slow due to the lack of targeted delivery methods. The biggest challenge in the use of siRNA-based therapies is delivery to target cells. There are many additional obstacles to in vivo delivery of siRNAs, such as degradation by endogenous enzymes and interaction with blood components leading to nonspecific uptake into cells, which govern biodistribution and availability of siRNA in the body. Naked unmodified synthetic siRNA including plasmid-carried-shRNA-expression constructs cannot penetrate cellular membranes, and therefore, systemic application is unlikely to be successful. The success of gene therapy by siRNAs relies on the development of safe, economical, and efficacious in vivo delivery systems into the target cells. Attenuated Salmonella have been employed recently as vectors to deliver silencing hairpin RNA (shRNA) expression plasmids into mammalian cells. This approach has achieved gene silencing in vitro and in vivo. The facultative anaerobic, invasive Salmonella have a natural tropism for solid tumors including metastatic tumors. Genetically modified, attenuated Salmonella have been used recently both as potential antitumor agents by themselves, and to deliver specific tumoricidal therapies. This chapter describes the use of attenuated bacteria as tumor-targeting delivery systems for cancer therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Hannon, G.J. (2002). RNA interference. Nature 418, 244–251.
Antoszczyk, S., Taira, K., and Kato, Y. (2006). Correlation of structure and activity of short hairpin RNA. Nucleic Acids Symp Ser (Oxf) 50, 295–296.
Hiroaki, K.H. and Taira, K. (2003). Short hairpin type of dsRNAs that are controlled by tRNAVal. promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells Nucleic Acids Res. 31, 700–707.
Zhang, L., Gao, L., Guo, B., et al. (2007). Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica. serovar Typhimurium carrying plasmid- based siRNAs Cancer Res. 67, 5859–5864.
Bermudes, D., Zheng, L.M., and King, L.C. (2002). Live bacteria as anticancer agents and tumor-selective protein deliver vectors. Curr. Opin. Drug. Discov. Devel. 5, 194–199.
Tjuvajev, J, Blasberg, R, Luo, X, et al. (2001). Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging J. Control Release 74, 313–315.
Zheng, L., Luo, X., Feng, M., et al. (2000). Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol. Res. 12, 127–135.
Forbes, N.S., Munn, L.L., Fukumura, D., et al. (2003). Sparse initial entrapment of systemically injected Salmonella typhimurium. leads to heterogeneous accumulation within tumors Cancer Res. 63, 5188–5193.
Pawelek, J.M., Low, K.B., and Bermudes, D. (2003). Bacteria as tumour-targeting vectors. Lancet Oncol. 4, 548–556.
Grosshans, H. and Slack, F.J. (2002). Micro-RNAs: small is plentiful. J. Cell Biol. 156, 17–21.
Amarzguioui, M. and Prydz, H. (2004). An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316, 1050–1058.
Paul, C.P., Good, P.D., Winer, I., et al. (2002). Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505–508.
Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553.
Brummelkamp, T.R., Bernards, R., and Agami, R (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243–247.
Lambin, P., Theys, J., Landuyt, W., et al. (1998). Colonization of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 4, 183–188.
Luo, X., Li, Z., Lin, S., et al. (2000). Antitumor effect of VNP20009, an attenuated Salmonella in murine tumor models. Ocol. Res. 12, 501–508.
Jazowiecka-Rakus, J and Szala, S (2004). Antitumour activity of Salmonella typhimurium. VNP20047 in B16(F10) murine melanoma model Acta Biochim. Pol. 51, 851–856.
Khan, S.A., Everest, P., and Servos, S (1998). A lethal role for lipid A in Salmonella infections. Mol. Microbiol. 29, 571–579.
Low, K.B., Ittensohn, M., Le, T., et al. (1999). Lipid A mutant salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat. Biotech. 17, 3–41.
Miller, S.I., Kukral, A.M., and Mekalanos, J.J. (1989). A two-component regulatory system (phoP phoQ) controls Salmonella-typhimurium virulence. Proc. Natl. Acad. Sci. USA 86, 5054–5058.
Ronson, C.W., Nixon, B.T., and Ausubel, F.M. (1987). Conserved domains in Bacterial regulatory proteins that respond to environmental stimuli. Cell 49, 579–581.
Ernst, R.K., Guina, T., and Miller, S.I. (1999). How intracellular bacteria, survive: surface modifications that promote resistance to host innate immune responses. J. Infect. Dis. 179, S326–S330.
VanCott, J.L., Chatfield, S.N., Roberts, M., et al. (1998). Regulation of host immune responses by modification of Salmonella virulence genes. Nat. Med. 4, 1247–1252.
Guo, L., Lim, K.B., Gunn, J.S., et al. (1997). Regulation of lipid A modifications by Salmonella typhimurium. virulence genes phoP-phoQ Science 276, 250–253.
Dang, L.H., Bettegowda, C., Huso, D.L., et al. (2001). Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. U S A 98, 15155–15160.
Low, K.B., Ittensohn, M., Luo, X., et al. (2004). Construction of VNP20009: A novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella. for parenteral administation in humans Methods Mol. Med. 90, 47–60.
Hohmann, E.L, Oletta, C.A., Killeen, K.P., et al. (1996). phoP/phoQ-deleted Salmonella typhi. (Ty800) is a safe and immunogenic single-dose typhoid fevr vaccine in volunteers J. Infect. Dis. 173, 1948–1014.
Hohmann, E.L., Oletta, C.A., and Miller, S.I. (1996). Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14, 19–24.
Koslowski, J.M., Fidler, I.J., Campbell, D., et al. (1984). Metastatic behavior of human tumor cell lines grown in the nude mice. Cancer Res. 44, 3522–3529.
Hoffman, R.M. (1999). Orthotopic metastatic mouse models for anticancer discovery and evaluation: a bridge to the clinic. Invest. New Drugs 17, 343–359.
Davies, J. and Jimenez, A. (1980). A new selective agent for eukayotic cloning vector. Am. J. Trop. Med. Hyg. 29, (5 Suppl.)1089–1092.
Bar-Nun, S., et al. (1983). G-418, an enlongation inhibitor of 80S ribosomes. Biochem. Biophys. Acta 741, 123–127.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Xu , DQ. et al. (2009). Bacterial Delivery of siRNAs: A New Approach to Solid Tumor Therapy. In: Sioud, M. (eds) siRNA and miRNA Gene Silencing. Methods in Molecular Biology, vol 487. Humana Press. https://doi.org/10.1007/978-1-60327-547-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-60327-547-7_8
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-546-0
Online ISBN: 978-1-60327-547-7
eBook Packages: Springer Protocols